Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Assets Average (2021 - 2025)

Candel Therapeutics' Assets Average history spans 3 years, with the latest figure at $45.6 million for Q4 2023.

  • On a quarterly basis, Assets Average fell 43.91% to $45.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $45.6 million, a 43.91% decrease, with the full-year FY2023 number at $59.4 million, down 28.76% from a year prior.
  • Assets Average hit $45.6 million in Q4 2023 for Candel Therapeutics, down from $54.4 million in the prior quarter.
  • Over the last five years, Assets Average for CADL hit a ceiling of $97.4 million in Q2 2022 and a floor of $45.6 million in Q4 2023.
  • Historically, Assets Average has averaged $75.5 million across 3 years, with a median of $76.9 million in 2022.
  • Biggest five-year swings in Assets Average: soared 40.73% in 2022 and later plummeted 43.91% in 2023.
  • Tracing CADL's Assets Average over 3 years: stood at $92.6 million in 2021, then decreased by 12.13% to $81.3 million in 2022, then plummeted by 43.91% to $45.6 million in 2023.
  • Business Quant data shows Assets Average for CADL at $45.6 million in Q4 2023, $54.4 million in Q3 2023, and $63.0 million in Q2 2023.